Bronchogen: Reference Overview and Reconstitution Notes

Bronchogen is a tiny lab-made peptide (a very short protein-like molecule built from just four amino acid building blocks) from the Khavinson family of bioregulators. It is connected to lung and airway research, is not FDA-approved, and is handled as a research-only material.

Bronchogen

What it is

Bronchogen is a lab-made short peptide (a protein-like molecule) called a tetrapeptide, meaning it is built from exactly four amino acid units. Its specific sequence is Ala-Glu-Asp-Leu (AEDL), and it has a molecular weight of about 446 g/mol. It belongs to the Khavinson family of peptide bioregulators, a group first described at the St. Petersburg Institute of Bioregulation and Gerontology.

This is a neutral reference entry covering its identity, regulatory status, and laboratory handling only.

Key point: Bronchogen is an investigational (still under study) lab-made four-unit peptide. Researchers study how it interacts with the bronchopulmonary system (the lungs and airways), but it is not FDA-approved for human or veterinary use.

Research context and categorization

Bronchogen is grouped with the Khavinson tissue bioregulators, specifically those linked to the bronchopulmonary (lung and airway) system. Research papers discuss it in relation to airway epithelial cells (the thin layer of cells that line the inside of the airways, like a skin on the inside of a tube). Scientists are investigating how short peptide sequences like this one may interact with gene-promoter regions (sections of DNA that act like on/off switches for specific genes). That interaction may affect genes tied to airway cell structure, mucin (the main ingredient in mucus), surfactant (a coating that keeps tiny airways from collapsing), and inflammation signals.

It has been studied in relation to bronchial epithelial cell growth, cell specialization, and airway tissue repair in preclinical (animal or cell-based) and lab models.

These uses are investigational and not confirmed or approved. Most published work comes from Russian preclinical and laboratory sources. Clear human data from controlled clinical trials is not established in the English-language literature. The research directions above should not be read as proven benefits.

Status

• Regulatory status: Not FDA-approved. Bronchogen is supplied and handled as a research-only material, and the published work on it is at the preclinical and investigational level. It is sold in Russia as a supplement, but that is not the same as FDA approval.
• Sport status: Not specifically listed by name on the WADA (World Anti-Doping Agency) Prohibited List. Researchers should note that WADA uses broad catch-all language for certain categories and updates the list every year. Always check the current official WADA Prohibited List to confirm status.

Reconstitution notes (general)

Bronchogen typically ships as a lyophilized (freeze-dried) powder that must be mixed with liquid before use in the lab. Working concentration follows a simple ratio: take the milligrams of peptide in the vial and divide by the milliliters of bacteriostatic water (water with a small preservative that stops bacteria from growing) that you add.

For example, a 20 mg vial mixed with 2 mL of water gives 10 mg/mL. The same vial mixed with 4 mL gives 5 mg/mL. A reconstitution calculator is available at peptide calculator.

Dilution and handling notes (compound-specific)

Working Concentrations

Bronchogen is commonly sold in 20 mg vials. A widely used starting point is adding about 2 mL to 4 mL of bacteriostatic water per vial. This places the working concentration in the 5 mg/mL to 10 mg/mL range.

The amount of water you choose is mostly about what concentration you need for your work, not a hard limit set by how well the peptide dissolves. This small, water-friendly peptide (scientists call this hydrophilic, meaning it readily mixes with water) dissolves easily.

Solubility and Mixing

Because Bronchogen is such a short peptide with only four building blocks, it dissolves quickly and produces a clear, colorless liquid. Think of it like table salt dropping into water. It does not tend to form a gel, go cloudy, or leave solid particles the way larger or more water-resistant peptides can. Because it dissolves so easily, aggressive mixing is not needed and can actually cause problems.

Step-by-Step Handling Guide

A few simple steps can reduce handling difficulties:

• Let both the sealed vial and the bacteriostatic water reach room temperature before mixing. This helps the powder dissolve cleanly.
• Add the water slowly, aiming the stream down the inside wall of the vial rather than directly onto the powder plug.
• Swirl gently or roll the vial between your palms, then let it rest. Do not shake it. Shaking whips air into the liquid and causes foaming.
• If the solution looks cloudy or has undissolved bits when concentrated, give it more time at room temperature or add a little more water. That usually clears it up.
• Keep the material out of direct light. If you will not use the whole vial quickly, divide it into small single-use portions (called aliquots) to avoid repeated freeze-thaw cycles, which can degrade the peptide over time.

Handling and storage

Store the reconstituted vial in a refrigerator at 2 to 8 degrees Celsius and keep it away from light. Wipe the rubber stopper with an alcohol swab before each puncture, and write the mixing date on the label.

Follow the general four-week refrigerated window for reconstituted peptides. Discard any vial that turns cloudy or discolored, or that shows floating particles or sediment.

Related reading

• Cardiogen
• Cartalax
• Cerebrolysin
• How Reconstitution Works
• How Long Does a Reconstituted Vial Last?

Tools and supplies

• peptide calculator
• Bacteriostatic Water 30 ml
• Gansulin Metal Reusable Pen
• 3 ml Glass Cartridges (10-pack)
• Complete Starter Kit

Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.

Frequently asked questions

What is the amino acid sequence and molecular weight of Bronchogen?

Bronchogen is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Leu (AEDL) and a molecular weight of approximately 446 g/mol, belonging to the Khavinson family of peptide bioregulators.

Is Bronchogen FDA-approved or listed on the WADA Prohibited List?

Bronchogen is not FDA-approved and is handled as a research-only investigational material. It is not specifically named on the WADA list, but researchers should always check the current official WADA Prohibited List for broad catch-all category language.

How do you reconstitute Bronchogen lyophilized powder for laboratory use?

Divide the vial's peptide mass (mg) by the volume of bacteriostatic water (mL) added to obtain working concentration (e.g., 20 mg ÷ 2 mL = 10 mg/mL). Add water slowly, swirl gently until dissolved, then label and store per lab protocol.

What the research community gets wrong about Bronchogen

Bronchogen is a well-known name in short-peptide work, but a few common assumptions can trip up handling and reading at the bench. Here are the ones worth checking.

• The name and the sequence are not the same thing. Vendors and papers use the label Bronchogen, but the four-letter order matters. Some published work writes the sequence as ADEL (Ala-Asp-Glu-Leu) while product pages often list AEDL (Ala-Glu-Asp-Leu). When you compare a vial label to a citation, read the actual amino acid order, not just the trade name.
• The gene findings are cell-culture observations, not settled outcomes. The main published study reports changes in the expression of airway genes (such as NKX2-1, SCGB1A1, and SCGB3A2) in cultured bronchial cells. That is a lab measurement in a dish, not a proven result in a whole system. Treat it as a research direction, not a fact.
• A bigger vial or higher concentration is not a different material. On the bench, dividing milligrams by milliliters of bacteriostatic water only sets concentration. It does not change what the molecule is. Because this is a small, water-friendly peptide, how well it dissolves is not the limiting factor for the water volume you pick.
• Being sold somewhere is not the same as being approved or clinically tested. Bronchogen is marketed as a supplement in Russia, but that says nothing about FDA approval or controlled human trial data. Those are separate questions, and the English-language clinical record is not established.
• There is no Bronchogen-specific stability chart to lean on. Published, compound-specific shelf-life numbers are sparse, so handling follows general short-peptide practice (kept cold, kept dark, split into single-use portions, mixed gently). Do not assume a special rule exists just because the peptide is well known.

From our bench: If you reconstitute a Bronchogen vial, we would like your firsthand notes. At the concentration you chose, how long did the powder take to fully dissolve with gentle swirling, and did the finished liquid read as clear and colorless or did anything haze or settle? Share your vial size, the water volume you added, and what you actually saw. Real observations only, no guesses.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. Khavinson VKh, Tendler SM, Vanyushin BF, et al. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014;192(5):781-91.
5. Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Moscow). 2015;80(3):310-22.